Orthofix Medical’s (OFIX) “Outperform” Rating Reiterated at Barrington Research

Barrington Research restated their outperform rating on shares of Orthofix Medical (NASDAQ:OFIX) in a report issued on Tuesday morning,Benzinga reports. The firm currently has a $18.00 price objective on the medical device company’s stock.

Several other equities analysts also recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Orthofix Medical in a research report on Thursday, January 22nd. Stifel Nicolaus initiated coverage on Orthofix Medical in a research report on Tuesday, October 28th. They set a “buy” rating and a $22.00 price target for the company. Finally, TD Cowen assumed coverage on Orthofix Medical in a report on Tuesday, January 27th. They set a “hold” rating and a $14.00 price target on the stock. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Orthofix Medical currently has an average rating of “Hold” and an average price target of $20.00.

Orthofix Medical Price Performance

Shares of OFIX opened at $13.77 on Tuesday. Orthofix Medical has a 12 month low of $10.24 and a 12 month high of $20.48. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.47 and a quick ratio of 1.38. The stock has a fifty day moving average price of $14.35 and a 200 day moving average price of $14.66. The company has a market cap of $545.29 million, a P/E ratio of -4.54 and a beta of 0.78.

Insiders Place Their Bets

In related news, CEO Massimo Calafiore sold 9,797 shares of the firm’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $15.21, for a total transaction of $149,012.37. Following the sale, the chief executive officer owned 217,237 shares of the company’s stock, valued at $3,304,174.77. This trade represents a 4.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Julie Andrews sold 4,873 shares of the business’s stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $14.38, for a total value of $70,073.74. Following the sale, the chief financial officer owned 58,039 shares in the company, valued at approximately $834,600.82. This trade represents a 7.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 24,270 shares of company stock valued at $370,958 over the last quarter. 1.30% of the stock is owned by corporate insiders.

Institutional Trading of Orthofix Medical

A number of large investors have recently bought and sold shares of the business. AQR Capital Management LLC increased its stake in shares of Orthofix Medical by 67.7% in the 1st quarter. AQR Capital Management LLC now owns 20,409 shares of the medical device company’s stock valued at $333,000 after acquiring an additional 8,241 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Orthofix Medical by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,561 shares of the medical device company’s stock valued at $335,000 after purchasing an additional 1,213 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Orthofix Medical during the first quarter valued at about $1,076,000. Strs Ohio bought a new position in shares of Orthofix Medical during the 1st quarter worth about $150,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Orthofix Medical in the 2nd quarter valued at about $147,000. 89.76% of the stock is currently owned by institutional investors and hedge funds.

About Orthofix Medical

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.